The disclosure discloses a probiotic mixed preparation with anti-influenza ability and application thereof, and belongs to the technical fields of microorganisms and medicines. The probiotic mixed preparation has anti-influenza effects, which are embodied in: (1) significantly reducing the degree of weight loss of influenza mice; (2) significantly improving the blood indexes of the influenza mice; (3) significantly improving the inflammation status of respiratory tract infections in the influenza mice; (4) significantly reducing the viral load in the lungs of the influenza mice (i.e., significantly inhibiting the replication and multiplication of influenza viruses in the influenza mice); and (5) significantly increasing the expression quantity of antiviral protein MxA in the lungs of the influenza mice. Therefore, the probiotic mixed preparation has great application prospects in preparation of a product for preventing and/or treating atopic dermatitis and even preventing and/or treating influenza.

Provided is a composition for preventing or improving impaired renal function, containing Bifidobacterium breve as an active ingredient. The composition for preventing or improving impaired renal function is capable of reducing blood creatinine levels. The composition for preventing or improving impaired renal function can also be used in a pharmaceutical composition or a food or beverage product composition.

The present disclosure relates to a method of producing lactic acid bacteria dual-coated with protein and polysaccharide by using a protein hydrolysate, and lactic acid bacteria having a dual coating, produced by the method. The lactic acid bacteria having a dual coating of protein and polysaccharide, produced according to the present disclosure, have very excellent dry-freezing viability, acid resistance and bile resistance. Accordingly, the lactic acid bacteria having a dual coating of protein and polysaccharide according to the present disclosure will be very useful for the production of fermented milk, processed milk, fermented soy products, processed foods, functional beverages, functional foods, common foods, etc.

The invention pertains to a nutritional composition comprising indigestible fiber and a lactic acid producing bacterium for normalizing the intestinal microbiota in amino acid-based formula fed infants or toddlers.

The invention pertains to a nutritional composition comprising indigestible fiber and a lactic acid producing bacterium for normalizing the intestinal microbiota in amino acid-based formula fed infants or toddlers.

A multilayer microencapsulated lactic bacteria and bifidobacteria, preferably bacteria with probiotic activity, and the use thereof to prepare a food product, supplement product, medical device or pharmaceutical composition or water- and/or fruit-based beverage are described. A process for preparing multilayer microencapsulated lactic bacteria and bifidobacteria, preferably bacteria with probiotic activity is described. A food product is described selected from water, water- and/or fruit-based beverages, milk, fresh whole milk, partially skimmed milk, powdered milk, cheese, fresh cheese, aged cheese, grated cheese, butter, margarine, yogurt, cream, milk- and chocolate-based custards, custards for sweets, jams and oily suspensions having bacteria, preferably multilayer microencapsulated lactic bacteria and bifidobacteria with probiotic activity.

A sweetener composition comprising xylose, a sugar alcohol and brown seaweed extract in solid form, preferably powdered or crystalline form. The sugar alcohol is preferably an erythritol and the brown seaweed extract is preferably obtained from Laminaria japonica. The sweetener composition can further comprise one or a combination of additional vitamins, minerals, probiotic cultures, and other plant-based extracts.

The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of non-replicating L. johnsonii La1 NCC533 (deposit number CNCM I-1225) for use in the treatment or prevention of disorders related to the immune system including infections.

The present invention is a yogurt product that may be consumed by dogs and other mammalian pets. The yogurt product is in an unflavored form comprising as essential constituents: (A) 0% to 88% by weight water; (B) 0.2% to 25% by weight of a no-fat protein component selected from the group consisting of skim milk and cultured skim milk; (C1) 0.001% to 6% by weight sugar component comprising: (C1) 0.001% to 6% polydextrose and (C2) 0.001% to 6% Glycoses and Galactoses; (D) 2% to 8% by weight milk derived solids; (E) 0.2% to 2.5% by weight stabilizers and emulsifiers; and (F) at least one probiotic microorganism. The yogurt product may be refrigerated and served as a mousse, frozen dessert, or as a fermented yogurt drink similar to Ayran or Kefir. A method for producing the yogurt product is also disclosed herein.

The disclosure provides compositions and dosage forms for promoting healthy microbial flora in a mammal, for example, a human. The disclosure further provides compositions and dosage forms for disrupting biofilm or preventing formation of biofilm containing pathogenic bacteria and/or pathogenic fungi in a particular region of a subject. The dosage forms contain (i) an isolated non-pathogenic fungal strain that is viable in the region of the subject, (ii) an isolated non-pathogenic bacterial strain that is viable in the region of the subject, and optionally (iii) an enzyme capable of disrupting the biofilm. The present disclosure also provides methods of disrupting a biofilm or preventing formation of a biofilm with such a composition or dosage form, methods of identifying a subject suitable for treatment with such a composition or dosage form, and methods of improving nutrient absorption using such a composition or dosage form.